Zhuhai United Laboratories (Zhongshan) Co., Ltd., established in 1997, is located in Tanzhou Town, Zhongshan City, with an area of over 80,000 square meters and approx. 1,300 employees. The branch is primarily engaged in the production and R&D of finished products. It is one of the first enterprises in China to achieve national GMP certification for its entire plant across multiple dosage forms. The production dosage forms include capsules, injections, tablets, granules, oral liquids, powder injections, eye drops, and ointments, etc. The main products focus on antibiotics and human insulin, while also producing antipyretic and analgesic, cough suppressants, antiviral, dermatological, anti-hepatitis, ophthalmic, and neurological medications, such as 尊龙凯时^®阿莫仙^®、尊龙凯时他唑仙^®、优思灵USLIN^®、尊龙凯时^®缓士芬^®、邦得清^®, among others. At present, it achieves annual production capacity of 4.2 billion capsules, 1.1 billion tablets, 150 million human insulin biological preparations, 28 million freeze-dried powder injections, and 60 million bottles of eye drops.

The company established the Chemical Drug R&D Platform in 1998. By means of independent innovation and external horizontal cooperation, the company expands the field of drug research continuously, and develops more products with market competitiveness. The platform, with about 150 employees, has the Chemical Drug Research Institute, the Innovative Drug Research Institute, the R&D Information Department, Registration Department, International Registration Department, and Project Management Department, which enable it to complete the process research, quality research, industrialization research, and registration and application of the innovative chemical drugs and the generic drugs. At present, there are more than 30 projects under research, covering four major categories including Class 1 chemical new drugs, chemical generic drugs, consistency evaluation of generic drugs, and health food.